Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review

There is uncertainty regarding the usefulness of CDK4/6-inhibitor-based therapy for hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2−), metastatic breast cancer (MBC), when CDK4/6 inhibitor treatment had previously failed. Furthermore, a biomarker for abemacicli...

Full description

Bibliographic Details
Main Authors: Yan Mao, Meng Lv, Yongmei Wang, Weihong Cao, Wenfeng Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
CDK4/6 inhibitor
breast cancer
metastatic
abemaciclib
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1022913/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1022913/full

Similar Items